Clinical trial
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic…
NCT00436930 · Hoag Memorial Hospital Presbyterian, Other · Completed
Key facts
| NCT number | NCT00436930 |
|---|---|
| Title | Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma |
| Official title | Randomized Phase II Trial of Autologous Vaccines Consisting of Adjuvant GM-CSF Plus Proliferating Tumor Cells Versus GM-CSF Plus Dendritic Cells Loaded With Proliferating Tumor Cells in Patients With Metastatic Melanoma (MAC-VAC) |
| Lead sponsor | Hoag Memorial Hospital Presbyterian, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | autologous tumor cell vaccine, sargramostim, therapeutic autologous dendritic cells |
| Enrollment | 200 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Feb 19, 2007 |
| Last update posted | Jan 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: